Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohnʼs Disease

Pharmacokinetics and Exposure–Efficacy Relationship of Adalimumab in Pediatric Patients with Moderate to Severe Crohnʼs Disease

(2015) Shringi Sharma et al.   INFLAMMATORY BOWEL DISEASES

Sa1153 Impact of Concomitant Immunosuppressant Use on Adalimumab Efficacy in Children With Moderately to Severely Active Crohn's Disease: Results From IMAgINE 1

(2014) Jeffrey S. Hyams et al.   GASTROENTEROLOGY

Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease

(2014) F.M. Ruemmele et al.   Journal of Crohns & Colitis

Doubling the infliximab dose versus halving the infusion intervals in Crohnʼs disease patients with loss of response

(2012) Lior Katz et al.   INFLAMMATORY BOWEL DISEASES

Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review

(2011) Vincent Billioud et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab

(2010) U. Kopylov et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Outcome Following Infliximab Therapy in Children With Ulcerative Colitis

(2010) Jeffrey S Hyams et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Dosage adjustment during long-term adalimumab treatment for Crohnʼs disease: Clinical efficacy and pharmacoeconomics

(2010) William J. Sandborn et al.   INFLAMMATORY BOWEL DISEASES

Natural history of Crohnʼs disease

(2009) Bénédicte Pigneur et al.   INFLAMMATORY BOWEL DISEASES

Long-term outcome of maintenance infliximab therapy in children with Crohnʼs disease

(2008) Jeffrey S. Hyams et al.   INFLAMMATORY BOWEL DISEASES